Pear Tree Pharmaceuticals, Inc. organized around the development and commercialization of pharmaceuticals for aging women. Products were offered that were designed to treat and prevent diseases, symptoms, and conditions associated with menopause and cancer chemotherapy. The firm's portfolio includes PT-200 for urogenital atrophy associated with menopause; PT-201 for urinary symptoms associated with menopause; and PT-101 for urogenital atrophy associated with menopause in women with an increased risk for breast cancer. During the Spring 2018, it was reported that the firm had merged with publicly traded Dare Bioscience( NASDAQ:DARE) a healthcare company focused on innovative products addressing womenâs reproductive health.
